The University of Oxford has become the first UK academic institution to receive support from the European Medicines Agency's (EMA) PRIority MEdicines (PRIME) scheme for its vaccine targeting the deadly Nipah virus.
Four new research studies looking into Long COVID in the community will receive funding worth £18.5 million from UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR).
While long COVID is slowly becoming more understood, ordinary COVID-19 patients are experiencing lasting effects - scientists discovered that 76% of people have atleast one recurring symptom, six months after the original illness.
Two divisions of Active Care Group – Christchurch Group and Remeo – discuss the importance of infection prevention and control in the healthcare sector in light of COVID-19.
